Current stock page

Catalysts

INSM Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Nov 13, 2026

INSMInsmed Incorporated

Healthcare / Biotechnology

Low Priority

Above Peers

NeutralEdge 6/10
$121.16+$3.09 (+2.62%)

Latest quote

  • Momentum
    61
  • Value
    55
  • Quality
    58
  • Risk resilience
    49
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Feb 18, 2027

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 57/100

Momentum 61/100 and sentiment — before the next covered event.

Recent coverage
5 articles

Updated Nov 15, 2026 · Sentiment 26.55%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 61/100AIQ Edge 6/10 Above Peers
Beat rate
25%
2 of 8 reported periods
Average surprise
-4.1%
Across covered historical reports
Latest result
-20.2%
Oct 29, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Oct 29, 2026—-$0.38-$0.46-20.2%$500.36M$524.43M
Aug 6, 2026—-$0.67-$0.06+91.1%$395.5M$425.49M
May 7, 2026—-$0.96-$0.76+21.1%$300.81M$305.96M
Feb 19, 2026—-$1.07-$1.54-43.9%$231.25M$263.84M
Oct 30, 2025—-$1.33-$1.75-31.6%$115.45M$142.34M
Aug 7, 2025—-$1.30-$1.70-30.8%$104.13M$107.42M
May 8, 2025—-$1.34-$1.42-6.0%$91.47M$92.82M
Feb 20, 2025—-$1.17-$1.32-12.8%$102.08M$104.44M

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
23
Buy
1
Hold
12-month analyst target
$191.13
+57.75% versus current price
Based on 24 analyst observations. Targets are estimates, not predictions.
Low target
$154.00
+27.10% vs latest price
Average target
$191.13
+57.75% vs latest price
High target
$213.00
+75.80% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateFeb 18, 2027

Next known earnings or reporting date.

EPS estimate-$0.31

Current analyst expectation for the upcoming report.

Revenue estimate$601.72M

Current analyst expectation for the upcoming report.

Sentiment score—

News pressure around the setup.

Momentum score61

Where event reaction would show up first.

AIQ score57/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
24
Average target
$191.13
Target upside
57.75%
Target range
$154.00 - $213.00

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
4
Neutral
1
Negative
0
seekingalpha.com · Oct 31, 2026

Insmed Incorporated (INSM) Q3 2026 Earnings Call Transcript

Insmed Incorporated (INSM) Q3 2026 Earnings Call October 29, 2026 8:00 AM EDTCompany ParticipantsWilliam Lewis - President, CEO & ChairmanSara...

gurufocus.com · Oct 5, 2026

Insmed CFO Sara Bonstein to Resign; INSM Reaffirms 2026 Revenue Guidance

On October 05, 2026, Insmed Incorporated (NASDAQ: INSM) announced that Chief Financial Officer Sara Bonstein will resign effective October 30, 2026, after nearl

gurufocus.com · Sep 30, 2026

INSM Maintains Overweight Rating -- Price Target Lowered to $207

Insmed (INSM) Analyst Rating Update On September 30, 2026, Barclays maintained an Overweight rating for Insmed (INSM). The price target for the company has b

insidermonkey.com · Sep 28, 2026

Insmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients?

Insmed Incorporated (NASDAQ:INSM) announced on September 21 that the FDA accepted its supplemental application for ARIKAYCE and granted priority review, setting January 28, 2027, as the target decision...

finance.yahoo.com · Sep 16, 2026

The Fund Exited Insmed (INSM) After the Investment Thesis Played Out

Parnassus Investments, an investment management company, released the “Parnassus Growth Equity Fund” second-quarter 2026 investor letter. The letter can be downloaded here. During the quarter, the Fund (Investor Shares) returned 17.49% (net of fees), outperforming the Russell 1000 Growth Index’s 16.74%. Holdings in Information Technology and Consumer Discretionary sectors boosted relative returns, while Communication Services […]

Open full news and sentiment

INSM Catalysts FAQ

What are the next catalysts for INSM stock?

INSM's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move INSM stock?

Upcoming events that could move INSM include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could INSM's next earnings report affect the stock?

INSM's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive INSM stock higher?

INSM could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt INSM stock?

INSM could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.